Fête & Global Leadership Award
26th Annual Fête & 2016 Global Leadership Award
The Philadelphia Chapter of
The French-American Chamber of Commerce
The 26th Annual Fête
President and Chief Executive Officer
Thursday, June 16th, 2016
Sheraton Society Hill Hotel Ballroom
One Dock Street near 2nd & Walnut Streets
Philadelphia, PA 19106
Meet Our Guest of Honor
President and Chief Executive Officer
Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval, and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8,000 employees in 50 countries.
Mr. Hoppenot joined Novartis in 2003, and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing.He started his career in 1983 with Rhone Poulenc, which later merged and went on to form Sanofi-Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School, near Paris. His wife Anne Hoppenot is the Honorary Consul of France in Princeton, NJ.
Special Thanks to Our Corporate Sponsors
Merci Beaucoup to Our Supporters
About Incyte Corporation
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. World-class science and R&D drives Incyte’s business and its commitment to improving the lives of patients with cancer and other diseases. The Company’s first commercial product, Jakafi, is the first and only approved treatment for myelofibrosis [i] and polycythemia vera [ii], two rare blood cancers knows as myeloproliferative neoplasms.
Incyte also has a diverse and growing clinical portfolio that continues to show great progress — the Company currently has 13 development molecules against 10 different targets and through its developed products and clinical collaborations has more than 80 ongoing clinical studies, both proof-of-concept and pivotal trials.
Headquartered in Wilmington, Delaware, Incyte Corporation has operations in Switzerland, France, Germany, The United Kingdom, Italy, Sweden, Spain, The Netherlands, and Austria. The Company currently employs more than 900 people. For more information, visit www.incyte.com.
[i] MF is a rare blood cancer in which scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. MF is a serious, chronic and progressive condition.
[ii] PV is a rare, chronic blood disease in which a person’s body makes too many red blood cells, and may also result in too many white blood cells or platelets. Too many red blood cells can cause the blood to thicken, leading to blood clots that block the flow of blood through the arteries and veins.
Previous Distinguished Honorees
(Formerly La Fête du Printemps Spring Gala)
2015 Arnaud Vaissié, Co-founder, Chairman & CEO, International SOS
2014 Dikembe Mutombo, NBA Legend & Humanitarian
2013 Tom Connelly, Chief Innovation Officer, DuPont
2012 Pierre Brondeau, President, CEO & Chairman of the Board, FMC Corporation
2011 Jean-Pierre Clamadieu, Chairman & Chief Executive Officer, Rhodia S.A. (now Solvay)
2010 Frank Baldino, Jr., Ph.D., Founder, Chairman & CEO, Cephalon Inc. (now Teva)
2009 Raj L. Gupta, Chairman & CEO, Rohm & Haas Company (now Dow Advanced Materials)
2008 Pierre Dufour, President & CEO, American Air Liquide; Sr. EVP & Director, L’Air Liquide S.A.
2007 Jean-François Phelizon, President & CEO, Saint-Gobain Corp.; SVP, Group Saint-Gobain
2006 Stephen K. Green, Group Chairman, HSBC Holdings plc
2005 Jean-François Dehecq, Chairman & CEO, Sanofi-Aventis Group
2004 Bernard Poussot, President, Wyeth Pharmaceuticals (now Pfizer)
2003 His Excellency Jean-David Levitte, Ambassador of France to the United States
2002 Jean-Pierre Loubinoux, Chairman and CEO, SNCF International
2001 Leonard A. Lauder, Chairman, The Estée Lauder Companies Inc.
2000 Robert Venturi & Denise Scott Brown, Architects and City Planners
1999 Anne d’Harnoncourt, CEO, & Joseph Rishel, Curator, Phila. Museum of Art/Rodin Museum
1998 Bruno Bonduelle, Chair & CEO, Groupe Bonduelle, President, Lille/Nord-Pas de Calais Dev.
1997 Jean-Pierre Garnier, President and COO, SmithKlineBeecham (now GlaxoSmithKline)
1996 Jean-Daniel Tordjman, Ambassador at Large for Int’l. Investment, Invest in France Mission
1995 Pierre Salinger, Consultant, Author, Journalist, Press Sec. to Presidents Kennedy & Johnson
1994 Serge Bellanger, President, FACC National & NY Chapter, EVP & General Manager, CIC, NY
1993 Madame Georges Pompidou, First Lady of France, Champion of the Elderly & Handicapped
1992 Jean-Daniel Tordjman, Minister Econ. & Comm. Affairs, Embassy of France, Washington, DC
1991 Jacques Andréani, Ambassador of France to the United States